On December 5, 2022 OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient’s own immune system to target and eradicate cancer, reported that Robert Arch, Ph.D., President and CEO of OncoSec, will be participating at the RHK Capital Disruptive Growth Conference in New York City (Press release, OncoSec Medical, DEC 5, 2022, View Source [SID1234624792]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of approximately 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers, and select RHK clients.

OncoSec’s’s webcast will be held on December 6, 2022 at 1:40 pm ET.